Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study

References

• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478–1484.
   PubMed Web of Science ®Google Scholar
• Ferdinand R, Mitchell SA, Batson S, et al. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 2012;3:51–76.
   PubMedGoogle Scholar
• Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006;91:452–459.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Nazha A, et al. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 2013;121:4867–4874.
   PubMed Web of Science ®Google Scholar
• Charles KS, Ramon L, Leelah N, et al. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago. West Indian Med J 2011;60:298–302.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981–1987.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Bendit I, Sanabani SS, Conchon M, et al. Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute. Acta Haematol 2012;128:223–232.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005;19:507–512.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63: 789–799.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011;118: 4541–4546; quiz 4759.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:1512–1516.
   PubMed Web of Science ®Google Scholar
• Gotta V, Buclin T, Csajka C, et al. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit 2013;35:150–167.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther 2010;88:809–813.
   PubMed Web of Science ®Google Scholar
• Cojbasic I, Macukanovic-Golubovic L.[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib]. Vojnosanit Pregl 2011;68:911–916.
   PubMed Web of Science ®Google Scholar
• Medhi K, Raina V, Kumar L, et al. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country. Leuk Lymphoma 2010;51:1850–1854.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Chouffai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010;3:272–276.
   PubMedGoogle Scholar
• Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271–275.
   PubMed Web of Science ®Google Scholar
• Oyekunle A, Osho PO, Aneke JC, et al. The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era. J Hematol Malig 2012;2:25–31.
   Google Scholar
• Pavlovsky C, Giere I, Moiraghi B, et al. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay. Clin Lymphoma Myeloma Leuk 2011;11:280–285.
   PubMed Web of Science ®Google Scholar
• Tantiworawit A, Power MM, Barnett MJ, et al. Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma 2012;53:1321–1326.
   PubMed Web of Science ®Google Scholar
• Al Sobhi E, Zahrani Z, Zevallos E, et al. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12:49–53.
   PubMed Web of Science ®Google Scholar
• Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 2010;4:315–323.
   PubMedGoogle Scholar
• Kayastha GK, Gurung P, Acharya PK, et al. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. BMC Blood Disord 2010;10:8.
   PubMedGoogle Scholar
• O’Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib (IM). Blood 2008;112(Suppl. 1): Abstract 186.
   Google Scholar
• Stagno F, Vigneri P, Del Fabro V, et al. Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol 2010;49: 506–508.
   PubMed Web of Science ®Google Scholar
• Aliano S, Cirmena G, Fugazza G, et al. Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy. Leuk Res Rep 2013;2:75–78.
   Google Scholar
• El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;125:187–195.
   PubMed Web of Science ®Google Scholar
• Al-Achkar W, Wafa A, Moassass F, et al. A unique cytogenetic abnormality, t(2;7)(p13.1;p21.3), in a Philadelphia-positive chronic myeloid leukemia. Oncol Lett 2012;4:209–212.
   PubMed Web of Science ®Google Scholar
• Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 2011;117:6793–6800.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
   PubMed Web of Science ®Google Scholar